Since 2017, Monash Partners’ innovative and transformative partnership with Equity Trustees, has provided over $900,000 for high impact research projects that directly benefit children and those suffering with cancer, heart disease and depression.
Monash Partners recognises the importance of philanthropy in supporting innovation in health and medical research. These funds enable unprecedented collaboration and improve the quality of life of patients, including the most vulnerable in our community.
The process for identifying projects include identification of leading clinical academics, including early career researchers, followed by submission of an expression of interest with competitive peer review.
We congratulate the following projects that have recently received funding through this partnership:
- Monitoring transcriptional evolution in acute myeloid leukaemia using circulating tumour DNA – the SNIPER assay, Dr Paul Yeh
- Paediatric data driven healthcare improvement, Dr Simon Craig
- The syncope-stopper study: Comparison of upfront pacing with standard care for high-risk patients with unexplained syncope, Dr Aleksandr Voskoboinik
- Discovering novel epigenetic targets for future combinational immunotherapy trials in brain cancer, Dr Elizabeth Ahern
- A biomarker platform for personalised management of cancer immunotherapy toxicity, Dr Miles Andrews
- Improving mental healthcare services – perceived need for mental health care, learning from what Australians say in two decades of national surveys, Dr Joanne Enticott
- Consumer and community involvement: implementing a model for consumer advisory panels across Monash Partners, Ms Joanna Ong.
These partnership projects are underpinned by our well-established collaborative model and are designed to rapidly transform research into healthcare delivery and direct patient benefit.
We will bring you more on these projects as they progress.
